ReviewNanoscale research letters2018
Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management.
Review in Nanoscale research letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 100 citations in OpenAlex.
- Eco-friendly synthesis and biomedical potential of silver nanoparticles using Pandanus dubius extract.Scientific reports · 2025Article
- Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Advances in Alzheimer's disease control approaches via carbon nanotubes.Nanomedicine (London, England) · 2025Review
- Emerging Promise of Green Synthesized Metallic Nanoparticles for the Management of Neurological Disorders.Current pharmaceutical design · 2025Review
- Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology.Frontiers in medicine · 2025Review
- Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.Current pharmaceutical design · 2025Review
- Nanotechnology-based Nose-to-brain Delivery in Epilepsy: A NovelApproach to Diagnosis and Treatment.Pharmaceutical nanotechnology · 2024Review
- Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review.Therapeutic delivery · 2024Review
- Bacterial cell permeability study by metal oxide and mixed metal oxide nanoparticles: analysis of the factors contributing to the antibacterial activity of nanoparticles.World journal of microbiology & biotechnology · 2023Article
- The Application of Biomaterials in Spinal Cord Injury.International journal of molecular sciences · 2023Review
- Metal Nanoparticles in Alzheimer's Disease.Journal of Alzheimer's disease reports · 2023Review
- Article
- Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders.Nanomaterials (Basel, Switzerland) · 2022Review
- Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases.Biomaterials science · 2020Article
- A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis.Molecular and cellular probes · 2020Article
- Assembly of gold nanoparticles using turnip yellow mosaic virus as an in-solution SERS sensor.RSC advances · 2019Article
- Role and prospects of regenerative biomaterials in the repair of spinal cord injury.Neural regeneration research · 2019Review
- Neurotoxicity of Nanomaterials: An Up-to-Date Overview.Nanomaterials (Basel, Switzerland) · 2019Review
- Biogenic fabrication and characterization of silver nanoparticles using aqueous-ethanolic extract of lichen (Biomaterials research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomaterials (NMs) are receiving remarkable attention due to their unique properties and structure. They vary from atoms and molecules along with those of bulk materials. They can be engineered to act as drug delivery vehicles to cross blood-brain barriers (BBBs) and utilized with better efficacy and safety to deliver specific molecules into targeted cells as compared to conventional system for neurological disorders. Depending on their properties, various metal chelators, gold nanoparticles (NPs), micelles, quantum dots, polymeric NPs, liposomes, solid lipid NPs, microparticles, carbon nanotubes, and fullerenes have been utilized for various purposes including the improvement of drug delivery system, treatment response assessment, diagnosis at early stage, and management of neurological disorder by using neuro-engineering. BBB regulates micro- and macromolecule penetration/movement, thus protecting it from many kinds of illness. This phenomenon also prevents drug delivery for the neurological disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis, amyotrophic lateral sclerosis, and primary brain tumors. For some neurological disorders (AD and PD), the environmental pollution was considered as a major cause, as observed that metal and/or metal oxide from different sources are inhaled and get deposited in the lungs/brain. Old age, obesity, diabetes, and cardiovascular disease are other factors for rapid deterioration of human health and onset of AD. In addition, gene mutations have also been examined to cause the early onset familial forms of AD. AD leads to cognitive impairment and plaque deposits in the brain leading to neuronal cell death. Based on these facts and considerations, this review elucidates the importance of frequently used metal chelators, NMs and/or NPs. The present review also discusses the current status and future challenges in terms of their application in drug delivery for neurological disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.